Annual report
2784.TEDINET S100R438
Period2022-04-01 → 2023-03-31
Filed2023-06-27
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 148
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥2.70T | 2022-04-01 → 2023-03-31 | Cons. | Net sales |
| Revenue | ¥2.59T | 2021-04-01 → 2022-03-31 | Cons. | Net sales |
| Revenue | ¥2.61T | 2020-04-01 → 2021-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥2.70T | 2019-04-01 → 2020-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥2.64T | 2018-04-01 → 2019-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥30.1bn | 2022-04-01 → 2023-03-31 | Cons. | Operating income |
| Operating income | ¥29.1bn | 2021-04-01 → 2022-03-31 | Cons. | Operating income |
| Ordinary income | ¥32.8bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥32.6bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥31.9bn | 2020-04-01 → 2021-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥57.2bn | 2019-04-01 → 2020-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥55.1bn | 2018-04-01 → 2019-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥38.6bn | 2022-04-01 → 2023-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥48.2bn | 2021-04-01 → 2022-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥25.8bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥32.2bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥24.5bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥40.3bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥41.7bn | 2018-04-01 → 2019-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥25.8bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss |
| Net income | ¥32.2bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss |
| Total assets | ¥1.34T | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥1.30T | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥1.32T | at 2021-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥1.35T | at 2020-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥1.34T | at 2019-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥851.5bn | at 2023-03-31 | Cons. | Liabilities |
| Total liabilities | ¥832.2bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥488.3bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥471.8bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥490.0bn | at 2021-03-31d | Cons. | Net assets |
| Net assets / equity | ¥474.9bn | at 2020-03-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥442.1bn | at 2019-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥160.1bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥180.4bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥158.8bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥179.1bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥169.1bn | at 2021-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥209.3bn | at 2020-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥205.1bn | at 2019-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥13.1bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥36.5bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥21.2bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥33.8bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥46.9bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥20.5bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | ¥2.3bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥4.7bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥17.0bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥12.9bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥12.9bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥29.2bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥14.5bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥12.6bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥24.9bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥127.42 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥153.57 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥115.75 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥190.26 | 2019-04-01 → 2020-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥195.91 | 2018-04-01 → 2019-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥2,411.89 | at 2023-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,330.36 | at 2022-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,313.66 | at 2021-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,237.89 | at 2020-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,083.03 | at 2019-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 36.4% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 36.2% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 37.2% | at 2021-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 35.0% | at 2020-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 32.9% | at 2019-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 5.4% | 2022-04-01 → 2023-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 6.7% | 2021-04-01 → 2022-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 5.1% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 8.8% | 2019-04-01 → 2020-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 9.5% | 2018-04-01 → 2019-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 11,772 | at 2023-03-31 | Cons. | Number of employees |
| Employees | 11,925 | at 2022-03-31 | Cons. | Number of employees |
| Employees | 12,045 | at 2021-03-31d | Cons. | Number of employees |
| Employees | 12,074 | at 2020-03-31d | Cons. | Number of employees |
| Employees | 12,076 | at 2019-03-31d | Cons. | Number of employees |
| Revenue | ¥22.2bn | 2022-04-01 → 2023-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥17.2bn | 2021-04-01 → 2022-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥25.3bn | 2020-04-01 → 2021-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥26.1bn | 2019-04-01 → 2020-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥22.0bn | 2018-04-01 → 2019-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Operating income | ¥20.1bn | 2022-04-01 → 2023-03-31 | Standalone | Operating income |
| Operating income | ¥15.2bn | 2021-04-01 → 2022-03-31 | Standalone | Operating income |
| Ordinary income | ¥20.3bn | 2022-04-01 → 2023-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥15.4bn | 2021-04-01 → 2022-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥23.7bn | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥24.5bn | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥20.2bn | 2018-04-01 → 2019-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥20.3bn | 2022-04-01 → 2023-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥13.7bn | 2021-04-01 → 2022-03-31 | Standalone | Income before income taxes |
| Net income | ¥20.4bn | 2022-04-01 → 2023-03-31 | Standalone | Profit loss |
| Net income | ¥13.6bn | 2021-04-01 → 2022-03-31 | Standalone | Profit loss |
| Net income | ¥23.9bn | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥22.3bn | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥20.2bn | 2018-04-01 → 2019-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥271.9bn | at 2023-03-31 | Standalone | Assets |
| Total assets | ¥265.3bn | at 2022-03-31 | Standalone | Assets |
| Total assets | ¥277.5bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥260.4bn | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥248.3bn | at 2019-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥15.1bn | at 2023-03-31 | Standalone | Liabilities |
| Total liabilities | ¥17.7bn | at 2022-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥256.8bn | at 2023-03-31 | Standalone | Net assets |
| Net assets / equity | ¥247.6bn | at 2022-03-31 | Standalone | Net assets |
| Net assets / equity | ¥261.3bn | at 2021-03-31d | Standalone | Net assets |
| Net assets / equity | ¥248.3bn | at 2020-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥236.1bn | at 2019-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥24.2bn | at 2023-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥21.0bn | at 2022-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥100.79 | 2022-04-01 → 2023-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥64.88 | 2021-04-01 → 2022-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥112.78 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥105.2 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥94.74 | 2018-04-01 → 2019-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥57 | 2022-04-01 → 2023-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥54 | 2021-04-01 → 2022-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥53 | 2020-04-01 → 2021-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥50 | 2019-04-01 → 2020-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥48 | 2018-04-01 → 2019-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥1,269.01 | at 2023-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,223.58 | at 2022-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,234.61 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,173.2 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,115.63 | at 2019-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 94.4% | at 2023-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 93.3% | at 2022-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 94.2% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 95.4% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 95.1% | at 2019-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 8.1% | 2022-04-01 → 2023-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 5.3% | 2021-04-01 → 2022-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 9.4% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 9.2% | 2019-04-01 → 2020-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 8.5% | 2018-04-01 → 2019-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 202,840,000 | at 2023-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 235,017,000 | at 2022-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 235,017,000 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 235,017,000 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 235,017,000 | at 2019-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 47 | at 2023-03-31 | Standalone | Number of employees |
| Employees | 44 | at 2022-03-31 | Standalone | Number of employees |
| Employees | 38 | at 2021-03-31d | Standalone | Number of employees |
| Employees | 38 | at 2020-03-31d | Standalone | Number of employees |
| Employees | 38 | at 2019-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 85
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2022-04-01 → 2023-03-31 | ¥2.0bn |
| Reconciling Itemsreconciling | depreciation | 2022-04-01 → 2023-03-31 | ¥2.3bn |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2023-03-31 | −¥31.2bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2023-03-31 | −¥31.2bn |
| Reconciling Itemsreconciling | segment assets | at 2023-03-31 | ¥24.7bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2023-03-31 | ¥315m |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥8.5bn |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥6.2bn |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | employees | at 2023-03-31 | 8680 pure |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥2.40T |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥2.38T |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥16.8bn |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | segment assets | at 2023-03-31 | ¥1.14T |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥27.0bn |
| Manufacturing Businessreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥2.0bn |
| Manufacturing Businessreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥3.6bn |
| Manufacturing Businessreportable segment | employees | at 2023-03-31 | 1383 pure |
| Manufacturing Businessreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥49.0bn |
| Manufacturing Businessreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥35.2bn |
| Manufacturing Businessreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥13.9bn |
| Manufacturing Businessreportable segment | segment assets | at 2023-03-31 | ¥70.1bn |
| Manufacturing Businessreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥420m |
| Medical Related Businessreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥912m |
| Medical Related Businessreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥396m |
| Medical Related Businessreportable segment | employees | at 2023-03-31 | 1187 pure |
| Medical Related Businessreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥36.2bn |
| Medical Related Businessreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥36.2bn |
| Medical Related Businessreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥0 |
| Medical Related Businessreportable segment | segment assets | at 2023-03-31 | ¥16.3bn |
| Medical Related Businessreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥330m |
| Self Medication Products Wholesaling Businessreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥251m |
| Self Medication Products Wholesaling Businessreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥326m |
| Self Medication Products Wholesaling Businessreportable segment | employees | at 2023-03-31 | 398 pure |
| Self Medication Products Wholesaling Businessreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥246.7bn |
| Self Medication Products Wholesaling Businessreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥246.2bn |
| Self Medication Products Wholesaling Businessreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥527m |
| Self Medication Products Wholesaling Businessreportable segment | segment assets | at 2023-03-31 | ¥89.7bn |
| Self Medication Products Wholesaling Businessreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥2.1bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2022-04-01 → 2023-03-31 | ¥11.7bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2022-04-01 → 2023-03-31 | ¥10.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2023-03-31 | ¥2.73T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2023-03-31 | ¥2.70T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥31.2bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2023-03-31 | ¥1.32T |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2023-03-31 | ¥29.8bn |
| Reconciling Itemsreconciling | capex | 2021-04-01 → 2022-03-31 | ¥2.1bn |
| Reconciling Itemsreconciling | depreciation | 2021-04-01 → 2022-03-31 | ¥2.1bn |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2022-03-31 | −¥29.1bn |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2022-03-31 | −¥29.1bn |
| Reconciling Itemsreconciling | segment assets | at 2022-03-31 | ¥15.5bn |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2022-03-31 | ¥332m |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥9.6bn |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥6.0bn |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥2.29T |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥2.27T |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥15.7bn |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | segment assets | at 2022-03-31 | ¥1.12T |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥24.8bn |
| Manufacturing Businessreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥3.9bn |
| Manufacturing Businessreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥3.3bn |
| Manufacturing Businessreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥47.4bn |
| Manufacturing Businessreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥34.6bn |
| Manufacturing Businessreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥12.8bn |
| Manufacturing Businessreportable segment | segment assets | at 2022-03-31 | ¥70.5bn |
| Manufacturing Businessreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥1.9bn |
| Medical Related Businessreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥426m |
| Medical Related Businessreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥387m |
| Medical Related Businessreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥34.5bn |
| Medical Related Businessreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥34.5bn |
| Medical Related Businessreportable segment | segment assets | at 2022-03-31 | ¥16.7bn |
| Medical Related Businessreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥183m |
| Self Medication Products Wholesaling Businessreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥306m |
| Self Medication Products Wholesaling Businessreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥357m |
| Self Medication Products Wholesaling Businessreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥244.8bn |
| Self Medication Products Wholesaling Businessreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥244.2bn |
| Self Medication Products Wholesaling Businessreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥610m |
| Self Medication Products Wholesaling Businessreportable segment | segment assets | at 2022-03-31 | ¥83.0bn |
| Self Medication Products Wholesaling Businessreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥1.9bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2021-04-01 → 2022-03-31 | ¥14.2bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2021-04-01 → 2022-03-31 | ¥10.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-04-01 → 2022-03-31 | ¥2.61T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-04-01 → 2022-03-31 | ¥2.59T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥29.1bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2022-03-31 | ¥1.29T |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-04-01 → 2022-03-31 | ¥28.8bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 2,066
| Item | Context | Value | Unit |
|---|---|---|---|
| Number of employees | Prior1YearInstant_NonConsolidatedMember | 44 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember | 47 | |
| Average number of temporary workers | Prior4YearInstant_NonConsolidatedMember | 1 | |
| Average number of temporary workers | Prior3YearInstant_NonConsolidatedMember | 1 | |
| Average number of temporary workers | Prior2YearInstant_NonConsolidatedMember | 1 | |
| Average number of temporary workers | Prior1YearInstant_NonConsolidatedMember | 1 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember | 1 | |
| Total shareholder return | Prior4YearInstant_NonConsolidatedMember | 1.351 | |
| Total shareholder return | Prior3YearInstant_NonConsolidatedMember | 0.892 | |
| Total shareholder return | Prior2YearInstant_NonConsolidatedMember | 0.965 | |
| Total shareholder return | Prior1YearInstant_NonConsolidatedMember | 0.804 | |
| Total shareholder return | CurrentYearInstant_NonConsolidatedMember | 0.827 | |
| Total return on share price index | Prior4YearInstant_NonConsolidatedMember | 0.950 | |
| Total return on share price index | Prior3YearInstant_NonConsolidatedMember | 0.859 | |
| Total return on share price index | Prior2YearInstant_NonConsolidatedMember | 1.221 | |
| Total return on share price index | Prior1YearInstant_NonConsolidatedMember | 1.246 | |
| Total return on share price index | CurrentYearInstant_NonConsolidatedMember | 1.318 | |
| Number of employees | CurrentYearInstant_jpcrp030000-asr_E02962-000EthicalPharmaceuticalsWholesalingBusinessReportableSegmentsMember | 8680 | |
| Average number of temporary workers | CurrentYearInstant_jpcrp030000-asr_E02962-000EthicalPharmaceuticalsWholesalingBusinessReportableSegmentsMember | 1637 | |
| Number of employees | CurrentYearInstant_jpcrp030000-asr_E02962-000SelfMedicationProductsWholesalingBusinessReportableSegmentsMember | 398 | |
| Average number of temporary workers | CurrentYearInstant_jpcrp030000-asr_E02962-000SelfMedicationProductsWholesalingBusinessReportableSegmentsMember | 7 | |
| Number of employees | CurrentYearInstant_jpcrp030000-asr_E02962-000ManufacturingBusinessReportableSegmentsMember | 1383 | |
| Average number of temporary workers | CurrentYearInstant_jpcrp030000-asr_E02962-000ManufacturingBusinessReportableSegmentsMember | 283 | |
| Number of employees | CurrentYearInstant_jpcrp030000-asr_E02962-000MedicalRelatedBusinessReportableSegmentsMember | 1187 | |
| Average number of temporary workers | CurrentYearInstant_jpcrp030000-asr_E02962-000MedicalRelatedBusinessReportableSegmentsMember | 409 | |
| Number of employees | CurrentYearInstant_CorporateSharedMember | 124 | |
| Average number of temporary workers | CurrentYearInstant_CorporateSharedMember | 6 | |
| Number of employees | CurrentYearInstant | 11772 | |
| Average number of temporary workers | CurrentYearInstant | 2345 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember | 47 | |
| Average age years information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 43.3 | |
| Average length of service years information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 16.0 | |
| Average annual salary information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 6961918 | JPY |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember | 1 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember_CorporateSharedMember | 47 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember_CorporateSharedMember | 1 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember | 47 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember | 1 | |
| Research and development expenses research and development activities | CurrentYearDuration | 2090000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E02962-000EthicalPharmaceuticalsWholesalingBusinessReportableSegmentsMember | 8059000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E02962-000SelfMedicationProductsWholesalingBusinessReportableSegmentsMember | 105000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E02962-000ManufacturingBusinessReportableSegmentsMember | 1829000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E02962-000MedicalRelatedBusinessReportableSegmentsMember | 684000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_ReportableSegmentsMember | 10679000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_UnallocatedAmountsAndEliminationMember | 337000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration | 11016000000 | JPY |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 202840000 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 202840000 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant | 202840000 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant | 202840000 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |